The most effective current HCC therapy, which has only a ~25% tumour response rate, depends on treating the tumour microenvironment by blocking PD-L1 to activate immune cells (Atezolizumab) plus inhibiting tumour vascularity (Bevacizumab) [11]. The gene discussed is CD274; the disease is hepatocellular carcinoma.